Takeda Pharmaceutical hit a one-year high however analysts forecast lack of upside in the near term. Despite a recent share price boost, the company had to trim its full-year guidance due to pipeline setbacks, causing share price to drop. As President Trump vowed to cut U.S. drug prices, Asian pharma stocks, including Takeda, also tumbled. Yet, there are positives, as the company clinched a Phase 3 win for an oral psoriasis drug, adding value for the shareholders. Despite
achieving a strong five-year run, some analysts wonder if it is too late to consider investing. The company’s pipeline kaizen is promising, with 6 drugs expected to contribute $20 billion annually. However, the current valuation might not be reflecting the company's true potential. Recent
FDA approvals and dip in share price in 2025 prompt to reassess its value. The company stands strong amid leadership transition and despite recent profit headwinds, the company favors future drug pipeline. Despite the CEO stepping down following a drop in shares, Takeda reels in positive phase 3 results, bolsters investment returns and projects growth path through strategic partnerships.
Takeda Pharmaceutical Stocks News Analytics from Wed, 16 Jan 2019 08:00:00 GMT to Tue, 30 Dec 2025 12:30:00 GMT -
Rating 2
- Innovation 4
- Information 6
- Rumor -3
